In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
|Videos|August 20, 2014
ASCO President Peter P. Yu on Attending AJMC's Patient-Centered Oncology Care Meeting
Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic.
Advertisement
Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic. Dr Yu will offer a keynote address a
Advertisement
Related to this article
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
3
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5